We are live on ! Find out more
TNGX icon

Tango Therapeutics

115 hedge funds and large institutions have $652M invested in Tango Therapeutics in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 30 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,265% more call options, than puts

Call options by funds: $1.32M | Put options by funds: $97K

342% more capital invested

Capital invested by funds: $147M → $652M (+$504M)

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

40% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 30

18.15% more ownership

Funds ownership: 99.24%117.39% (+18%)

6% less funds holding

Funds holding: 122115 (-7)

25% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 28

Holders
115
Holders Change
-7
Holders Change %
-5.74%
% of All Funds
1.51%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.09%
New
21
Increased
42
Reduced
30
Closed
28
Calls
$1.32M
Puts
$97K
Net Calls
+$1.23M
Net Calls Change
+$1.23M
Name Holding Trade Value Shares
Change
Change in
Stake
TGI
1
TRV GP IV
Massachusetts
$86.3M
TCM
2
TCG Crossover Management
California
$55M
EC
3
EcoR1 Capital
California
$54.4M
BCM
4
Boxer Capital Management
California
$50M -$1.51M -609,514 -6%
FCM
5
Farallon Capital Management
California
$46.9M +$11.2M +4,546,070 +99%
WP
6
Woodline Partners
California
$30.9M +$13.7M +5,523,718 +1,091%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$30.2M +$14.6M +5,905,349 New
NI
8
Nextech Invest
Switzerland
$28.3M
BlackRock
9
BlackRock
New York
$28M +$3.54M +1,431,254 +35%
GS
10
Gilead Sciences
California
$24.9M
Vanguard Group
11
Vanguard Group
Pennsylvania
$20.6M +$374K +151,255 +4%
NCM
12
Nantahala Capital Management
Connecticut
$17.6M +$1.12M +451,611 +15%
SL
13
Siren LLC
Connecticut
$17.2M +$1.98M +799,472 +31%
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
$16.6M +$69K +27,892 +0.9%
T. Rowe Price Investment Management
15
T. Rowe Price Investment Management
Maryland
$16.2M -$354K -143,223 -4%
BCLSI
16
Bain Capital Life Sciences Investors
Massachusetts
$13.9M
RCM
17
RA Capital Management
Massachusetts
$10.2M +$4.95M +2,000,000 New
Millennium Management
18
Millennium Management
New York
$9.07M +$745K +301,372 +20%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$9.06M +$953K +385,476 +28%
Marshall Wace
20
Marshall Wace
United Kingdom
$8.92M -$246K -99,472 -5%
CC
21
Commodore Capital
New York
$7.68M +$3.71M +1,500,000 New
State Street
22
State Street
Massachusetts
$7.08M +$589K +238,243 +21%
BOCH
23
Blue Owl Capital Holdings
New York
$4.17M -$3.23M -1,307,236 -62%
SCM
24
Soleus Capital Management
Connecticut
$3.74M +$1.8M +730,000 New
CS
25
Candriam SCA
Luxembourg
$3.63M +$1.75M +708,812 New

TNGX Hedge Fund Activity: Q2 2025 in Review

115 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q2 2025, worth a combined $652M — up 342% from $147M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of TNGX and 21 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 42 added.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $14.6M. The largest seller was Blue Owl Capital Holdings, cutting an estimated $3.23M.

  • 115 institutional investors held Tango Therapeutics (TNGX) as of Q2 2025, down from 122 in Q1 2025.
  • Funds reported $652M of Tango Therapeutics stock for Q2 2025, up 342% quarter-over-quarter.
  • 21 funds opened new Tango Therapeutics positions in Q2 2025 and 28 closed out, a net change of -7 holders.
  • The largest Tango Therapeutics buyer in Q2 2025 was Adage Capital Partners, an estimated $14.6M added.
  • The largest Tango Therapeutics seller in Q2 2025 was Blue Owl Capital Holdings, an estimated $3.23M sold.

Based on aggregated 13F filings for Q2 2025.